Jagadeesh Ganji
Cardiovascular Disease · Greensboro, NCNPI 1306942578
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Esperion Therapeutics, Inc. at 51.5% of the total. Reporting peaked in 2021 at $10,388 and has fallen 84.4% since, to $1,617 in 2025.
Across 235 payments — averaging $100.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$12K
- Sanofi-aventis U.S. LLC$3K
- Medtronic$2K
- Amgen$1K
- Boston Scientific$785
- Bayer$589
- plus $4K from 28 others
Across 445 payments — averaging $3705.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$538K
- American Regent$291K
- Eli Lilly$190K
- AstraZeneca$151K
- Amgen$100K
- Boston Scientific$95K
- plus $284K from 6 others
What the payments were for
- Consulting fees$2,50411%
- Speaking & faculty fees$11,58049%
- Travel & lodging$1,9898%
- Food & beverage$7,29731%
- Education$1741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 11 | $12,117 |
| Sanofi-aventis U.S. LLC | 4 | $2,576 |
| Medtronic(2 entities) | 21 | $2,335 |
| Amgen | 38 | $1,097 |
| Boston Scientific | 4 | $785 |
| Bayer | 6 | $589 |
| United Therapeutics Corporation | 39 | $458 |
| Abbott | 7 | $393 |
| Abiomed | 8 | $345 |
| Teleflex LLC | 3 | $327 |
| Actelion Pharmaceuticals US, Inc. | 8 | $318 |
| Novartis | 18 | $302 |
| E.r. Squibb & Sons, L.L.C. | 9 | $191 |
| Angiodynamics, Inc. | 2 | $165 |
| W. L. Gore & Associates, Inc. | 3 | $162 |
| Boehringer Ingelheim | 3 | $152 |
| Pfizer | 5 | $138 |
| Alnylam Pharmaceuticals Inc. | 1 | $123 |
| Cardiovascular Systems Inc. | 1 | $115 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $108 |
| Lilly USA, LLC | 1 | $100 |
| Chiesi USA, Inc. | 2 | $90 |
| Johnson & Johnson | 11 | $81 |
| AstraZeneca | 5 | $74 |
| Regeneron Healthcare Solutions, Inc. | 3 | $72 |
| Shockwave Medical, Inc | 1 | $67 |
| Novo Nordisk | 3 | $56 |
| Irhythm Technologies, Inc. | 3 | $45 |
| Biosense Webster, Inc. | 1 | $44 |
| Acist Medical Systems, Inc. | 1 | $36 |
| Cvrx, Inc. | 2 | $30 |
| Biotronik Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLIZET$12,077
- NEXLETOL$12,077
- MULTAQ$2,504
- ONYX FRONTIER$1,364
- GENERAL VASCULAR ACCESS$772
- Repatha$263
- ORENITRAM$243
- JARDIANCE$223
- Impella$147
- GORE CARDIOFORM Septal Occluder$141
- SYMPLICITY G3$129
- UPTRAVI$125
- OPSUMIT$125
- TURNPIKE$124
- ONPATTRO$123
- REMODULIN$120
- TYVASO$120
- ESPRIT$116
- Diamondback Peripheral$115
- GUIDELINER$113
How this compares
$23,544 in reported general payments places this provider in the 85th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 539 | $539,019 |
| TracleerBosentan | 12 | $268,994 |
| XareltoRivaroxaban | 192 | $230,782 |
| AdempasRiociguat | 13 | $169,524 |
| EntrestoSacubitril/Valsartan | 163 | $162,274 |
| Orenitram ErTreprostinil Diolamine | 12 | $152,743 |
| JardianceEmpagliflozin | 130 | $98,365 |
| OzempicSemaglutide | 69 | $95,208 |
| Repatha SureclickEvolocumab | 90 | $93,778 |
| FarxigaDapagliflozin Propanediol | 79 | $79,006 |
| MultaqDronedarone Hcl | 16 | $31,843 |
| Dofetilide | 33 | $12,699 |
| BrilintaTicagrelor | 16 | $12,598 |
| NexlizetBempedoic Acid/Ezetimibe | 19 | $12,132 |
| CorlanorIvabradine Hcl | 14 | $11,243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $138 | $539,019539 claims |
| Actelion Pharmaceuticals US, Inc.Tracleer | $318 | $268,99412 claims |
| Johnson & JohnsonXarelto | $81 | $230,782192 claims |
| BayerAdempas, Kerendia | $589 | $177,17525 claims |
| NovartisEntresto | $302 | $162,274163 claims |
| Boehringer IngelheimJardiance | $152 | $98,365130 claims |
| Novo NordiskOzempic | $56 | $95,20869 claims |
| AstraZenecaFarxiga, Brilinta | $74 | $91,60495 claims |
| Sanofi-aventis U.S. LLCMultaq | $2,576 | $31,84316 claims |
| Esperion Therapeutics, Inc.Nexlizet | $12,117 | $12,13219 claims |
| AmgenCorlanor | $1,097 | $11,24314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Greensboro
- Tiffany RandolphGreensboro$133K
- Cameron LambertGreensboro$99K
- Wesley O'NealGreensboro$85K
- Kenneth HiltyGreensboro$51K
- Katarina NelsonGreensboro$46K
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Michael RinaldiCharlotte$722K
- Markus SchererCharlotte$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.